Biodesix Inc (BDSX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$26.18-1.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Biodesix aims to grow revenue to about $111 million in 2026. Revenue grew from $20 million in 2025-Q2 to $25.5 million in 2026-Q1. Management targets adjusted EBITDA positivity by end of 2025. The company beat earnings in recent quarters.
Biodesix is still loss-making and has negative free cash flow. Earnings estimates remain negative through 2027. The recent sharp stock selloff shows investor doubts. The company may miss its profit goals.
The market expects about 24% revenue growth. Our fair value is well above the Street median, showing optimism. The stock price fell 17% from its high, reflecting recent worries.
Breaks if: Adjusted EBITDA remains negative after 2025-Q4
Biodesix aims to achieve adjusted EBITDA positivity by the end of Q4 2025.
Breaks if: Revenue falls below $108 million in FY26
Maintain and achieve full-year 2026 revenue guidance of $108-114 million, reflecting approximately 25% growth over 2025.
Stated as a priority in 2 of last 2 quarters. Management maintained FY 2026 revenue guidance of $108-114 million, reflecting about 25% growth over 2025's $86 million revenue guidance. Actual revenue grew from $37.976 million in first half 2025 to $52.416 million in first half 2026, supporting the growth trajectory. The company is delivering on this revenue growth priority.
“Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth”
“Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth”
Breaks if: Quarterly revenue falls below $20 million in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. The company is currently loss-making but is focused on revenue growth and improving profitability, making the thesis state somewhat weakened due to recent performance changes.
The market seems to have priced in a low expectations gap, suggesting that BDSX is viewed as relatively cheap compared to peers. However, the valuation has recently fallen, indicating that the market may be cautious about future performance.
Management is on track with revenue growth and expanding diagnostic testing, which shows promise for future performance. However, the adjusted EBITDA profitability goal is mixed, reflecting ongoing challenges in achieving profitability despite improvements.
The thesis hinges on management's ability to maintain or increase revenue guidance and the performance of sector bellwethers. Additionally, broader economic conditions, such as job growth and recession fears, could significantly impact BDSX's performance.
In the next 1-3 years, BDSX's prospects will depend on its execution of growth strategies and external economic factors. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation fell by 15.7 points (from 51.7 to 36.0).
Yes, our read has weakened. The latest earnings beat provided some support for the thesis. However, a sharp drop in the stock price suggests the market may be repricing the thesis. Recent financial performance has dropped to the bottom half of its industry.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.